Philip Serlin resigned as director of Vascular Biogenics Ltd.
Serlin's resignation did not result from any disagreement with Vascular Biogenics on any matter relating to its operations, policies or practices, according to the company.
Israel-based Vascular Biogenics is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of treatments for cancer.
